Lord O’Neill Blames Governments And Pharma For Faltering AMR Progress
O'Neill assessed the antibiotic 'State Of Play' in a Chatham House AMR progress report
Three years after completion of his high-profile AMR Review, Jim O’Neill warns that global progress on antimicrobial resistance has slowed dangerously.
You may also be interested in...
Jim O’Neill, the British economist who helped put the dangers of antimicrobial resistance firmly on the world stage, says he’s “frustrated” by the G20’s lack of focus on AMR during its Japan summit.
Shares in Iovance Biotherapeutics have soared this week amid reports the US clinical-stage biotechnology company is in active M&A talks.
New safety concerns over Novartis's anti-VEGF eye injection drug will likely cut its uptake and reduce its competitive threat to Bayer and Regeneron's VEGF inhibitor Eylea.